Effect of eplerenon on heart failure in patients with paroxysmal Atrial Fibrillation and ejection fraction ≥ 45%. | ||
| Aswan University Medical Journal | ||
| Article 2, Volume 4, Issue 3, December 2024, Pages 12-16 PDF (753.6 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/aumj.2024.312813.1134 | ||
| Authors | ||
| Ayman M. Ibrahim1; Ahmed M Abdel Galil2; ahmed moshref abdelsattar1; soud Mohammed elsoughier* 1 | ||
| 1Department of cardiology, faculty of medicine, Aswan university | ||
| 2Department of cardiology, faculty of medicine, Assiut university | ||
| Abstract | ||
| Background: Atrial fibrillation (AF) is the commonest form of sustained arrhythmia; it increases the risk of stroke, heart failure and mortality. So, preventing AF episodes is needed. The aim of the present study was to investigate the effect of eplerenon (25mg) on cardiac functions in patients with paroxysmal AF. Methods: This was a Prospective Comparative Study, conducted at Cardiology department at Aswan University Hospital, on 100 patients with non valvular and paroxysmal AF, confirmed by electrocardiography divided into 2 groups: (Group A): 50 patients received eplerenon (25 mg) + amiodarone. (Group B): 50 patients received amiodarone only (control group). Results: After 6 months of follow up, we noticed a significant increase in left ventricular ejection fraction in group of patients who received eplerenon plus amiodarone in comparison with the group that received amiodarone only. Conclusion: Eplerenon is an effective drug in improvement of cardiac function in patients with non-valvular and paroxysmal AF when added to antiarrhythmic treatment (Amiodarone) . | ||
| Keywords | ||
| Eplernon; atrial fibrillation; LVEF | ||
|
Statistics Article View: 90 PDF Download: 48 |
||
